Cadence Pharmaceuticals, a biopharmaceutical company developing drug candidates for use in hospitals, set the terms for its IPO on Tuesday. The San Diego-based company plans to offer 6 million shares at a range of $11-$13, giving the deal a proposed market cap of $352 million. Merrill Lynch, Deutsche Bank, Pacific Growth Equities and JMP Securities are set to manage the deal, which is expected to price the week of October 23rd.
